These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23614008)

  • 1. The efficacy of bevacizumab compared with other targeted drugs for patients with advanced NSCLC: a meta-analysis from 30 randomized controlled clinical trials.
    Cui J; Cai X; Zhu M; Liu T; Zhao N
    PLoS One; 2013; 8(4):e62038. PubMed ID: 23614008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
    Sun L; Ma JT; Zhang SL; Zou HW; Han CB
    Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis.
    Yang K; Wang YJ; Chen XR; Chen HN
    Clin Drug Investig; 2010; 30(4):229-41. PubMed ID: 20225906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bevacizumab combined with chemotherapy for advanced non-small cell lung cancer: a meta-analysis].
    Zhang T; Yuan S; Wang Z; Zhang Q; Zhao P; Shan L
    Zhongguo Fei Ai Za Zhi; 2013 Feb; 16(2):82-90. PubMed ID: 23425900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Lima AB; Macedo LT; Sasse AD
    PLoS One; 2011; 6(8):e22681. PubMed ID: 21829644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach.
    Tassinari D; Sartori S; Papi M; Drudi F; Castellani C; Carloni F; Tombesi P; Lazzari-Agli L
    Oncology; 2011; 80(5-6):350-8. PubMed ID: 21791945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis.
    Botrel TE; Clark O; Clark L; Paladini L; Faleiros E; Pegoretti B
    Lung Cancer; 2011 Oct; 74(1):89-97. PubMed ID: 21377753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
    Wagner AD; Thomssen C; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab in non-small cell lung cancer.
    Di Costanzo F; Mazzoni F; Micol Mela M; Antonuzzo L; Checcacci D; Saggese M; Di Costanzo F
    Drugs; 2008; 68(6):737-46. PubMed ID: 18416583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-angiogenic therapies for metastatic colorectal cancer.
    Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer.
    Soria JC; Mauguen A; Reck M; Sandler AB; Saijo N; Johnson DH; Burcoveanu D; Fukuoka M; Besse B; Pignon JP;
    Ann Oncol; 2013 Jan; 24(1):20-30. PubMed ID: 23180113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic Therapy in Advanced Non-small-cell Lung Cancer: A Meta-analysis of Phase III Randomized Trials.
    Raphael J; Chan K; Karim S; Kerbel R; Lam H; Santos KD; Saluja R; Verma S
    Clin Lung Cancer; 2017 Jul; 18(4):345-353.e5. PubMed ID: 28188101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
    Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
    Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).
    Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Marsland T; Patel T; Rubin M; White L; Yang JC; Klughammer B; Colburn D; Miller V; Johnson BE
    J Thorac Oncol; 2014 Sep; 9(9):1411-7. PubMed ID: 25122437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of angiogenesis inhibitors in the treatment of elderly patients with advanced non-small-cell lung cancer: A meta-analysis of eleven randomized controlled trials.
    Tian RH; Wu X; Liu X; Yang JW; Ji HL; Yan YJ
    J Cancer Res Ther; 2016; 12(2):571-5. PubMed ID: 27461612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.
    Li BT; Barnes TA; Chan DL; Naidoo J; Lee A; Khasraw M; Marx GM; Kris MG; Clarke SJ; Drilon A; Rudin CM; Pavlakis N
    Lung Cancer; 2016 Dec; 102():21-27. PubMed ID: 27987583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials.
    Xiao YY; Zhan P; Yuan DM; Liu HB; Lv TF; Song Y; Shi Y
    Eur J Clin Pharmacol; 2013 Feb; 69(2):151-9. PubMed ID: 22729611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.
    Khan M; Lin J; Liao G; Tian Y; Liang Y; Li R; Liu M; Yuan Y
    Medicine (Baltimore); 2018 Aug; 97(33):e11936. PubMed ID: 30113497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
    Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
    Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.